CytomX Therapeutics (CTMX) Competitors $2.18 -0.10 (-4.39%) Closing price 09/8/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.02%) As of 09/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. PGEN, ETNB, XERS, ABCL, EVO, COLL, NTLA, CVAC, ELVN, and CALTShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Precigen (PGEN), 89BIO (ETNB), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), CureVac (CVAC), Enliven Therapeutics (ELVN), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Precigen 89BIO Xeris Biopharma AbCellera Biologics Evotec Collegium Pharmaceutical Intellia Therapeutics CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) CytomX Therapeutics (NASDAQ:CTMX) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Which has stronger valuation & earnings, CTMX or PGEN? CytomX Therapeutics has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M2.60$31.87M$0.563.89Precigen$4.34M285.61-$126.24M-$0.42-9.90 Which has more volatility and risk, CTMX or PGEN? CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Do analysts rate CTMX or PGEN? CytomX Therapeutics presently has a consensus target price of $5.75, suggesting a potential upside of 163.76%. Precigen has a consensus target price of $8.25, suggesting a potential upside of 98.32%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Precigen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is CTMX or PGEN more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Precigen's net margin of -2,868.66%. CytomX Therapeutics' return on equity of 158.70% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Precigen -2,868.66%-842.83%-78.98% Do insiders and institutionals hold more shares of CTMX or PGEN? 67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Comparatively, 47.1% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer CTMX or PGEN? In the previous week, Precigen had 13 more articles in the media than CytomX Therapeutics. MarketBeat recorded 14 mentions for Precigen and 1 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.67 beat Precigen's score of 0.98 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCytomX Therapeutics beats Precigen on 12 of the 15 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$376M$3.17B$5.81B$9.93BDividend YieldN/A2.27%6.70%4.53%P/E Ratio3.8921.2975.7726.46Price / Sales2.60291.83475.4287.71Price / Cash6.3044.1225.7029.11Price / Book-218.009.7811.916.14Net Income$31.87M-$53.22M$3.28B$265.92M7 Day Performance4.81%1.85%1.00%8.05%1 Month Performance-7.23%11.44%10.64%13.39%1 Year Performance74.40%13.32%65.59%29.12% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.2591 of 5 stars$2.18-4.4%$5.75+163.8%+81.7%$376M$138.10M3.89170Positive NewsPGENPrecigen4.5397 of 5 stars$4.51-0.9%$8.25+82.9%+342.6%$1.34B$3.92M-10.74190ETNB89BIO2.9472 of 5 stars$9.03-4.1%$26.63+194.9%+1.2%$1.34BN/A-2.5040News CoveragePositive NewsAnalyst RevisionXERSXeris Biopharma3.4955 of 5 stars$7.83-0.9%$7.08-9.5%+209.6%$1.26B$203.07M-37.28290Positive NewsShort Interest ↓ABCLAbCellera Biologics2.2331 of 5 stars$4.18-2.8%$8.00+91.4%+74.5%$1.25B$28.83M-7.60500EVOEvotec1.702 of 5 stars$3.50-0.3%$5.40+54.3%+3.9%$1.24B$862.40M0.004,827COLLCollegium Pharmaceutical3.2361 of 5 stars$38.80+1.2%$42.33+9.1%+1.5%$1.22B$631.45M37.31210NTLAIntellia Therapeutics4.6859 of 5 stars$11.35-2.2%$29.05+156.0%-40.0%$1.22B$57.88M-2.42600Positive NewsAnalyst UpgradeCVACCureVac4.6672 of 5 stars$5.37flat$6.83+27.3%+95.3%$1.20B$579.18M5.59880Positive NewsELVNEnliven Therapeutics3.025 of 5 stars$20.27-0.4%$41.20+103.3%-6.6%$1.20BN/A-10.1450CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Precigen Competitors 89BIO Competitors Xeris Biopharma Competitors AbCellera Biologics Competitors Evotec Competitors Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors CureVac Competitors Enliven Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts